Atlas Trials

Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)

Clinical trial NCT05007509 · COMPLETED

Trial details

NCT number
NCT05007509
Sponsor
Laboratorios Hipra, S.A.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Covid19SARS CoV 2 Infection
Start date
2021-08-16
Primary completion
2021-09-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.